Dendritic cell immunotherapy for cancer: Application to low‐grade lymphoma and multiple myeloma
Authors:
- 1 October 1999
- journal article
- review article
- Published by Wiley in Immunology & Cell Biology
- Vol. 77 (5) , 451-459
Abstract
The confirmation that most cancers express one or more molecular changes, which may act as tumour‐associated antigens (TAA), combined with the knowledge that T lymphocytes recognize even single amino acid differences in MHC presented peptides has stimulated renewed clinical interest in immunotherapeutic strategies. Dendritic cells (DC) are now recognized as specialist antigen‐presenting cells, which initiate, direct and regulate immune responses. Recent data suggest that DC are not recruited into, or activated by, cancers and that other abnormalities in DC function are associated with malignancy, including multiple myeloma. This provides a rationale for designing immunotherapeutic strategies, which exploit DC as nature's adjuvant either in vivo or in vitro. Low‐grade lymphoma and multiple myeloma are slowly progressive malignancies, which generally express a unique immunoglobulin idiotype as a potential TAA. Data from animal models and clinical studies suggest that DC‐based immunotherapy strategies, applied when the patient has minimal residual disease, may improve the long‐term prognosis in these diseases.Keywords
This publication has 84 references indexed in Scilit:
- Broadened Clinical Utility of Gene Gun-Mediated, Granulocyte-Macrophage Colony-Stimulating Factor cDNA-Based Tumor Cell Vaccines as Demonstrated with a Mouse Myeloma ModelHuman Gene Therapy, 1998
- Review: Dendritic Cells and Cancer: Progress Toward a New Cellular TherapyJournal of Hematotherapy, 1997
- The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myelomaLeukemia, 1997
- Vaccination of melanoma patients with peptide-pulsed dendritic cellsMelanoma Research, 1997
- Strategies for immunoprophylaxis and immunotherapy of papillomavirusesClinics in Dermatology, 1997
- Dendritic Cells in Antitumor Immune ResponsesCellular Immunology, 1996
- Myeloma: New aspects of biology, prognosis and treatmentPathology, 1996
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.Journal of Experimental Medicine, 1994
- T cell clones specific for p21 ras‐derived peptides: Characterization of their fine specificity and HLA restrictionEuropean Journal of Immunology, 1993
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982